Portal de Periódicos da CAPES

Influence of human papillomavirus and p16INK4a on treatment outcome of patients with anal cancer

2014; Elsevier BV; Volume: 113; Issue: 3 Linguagem: Inglês

10.1016/j.radonc.2014.11.013

1879-0887

Stefan A. Koerber, Clara Schoneweg, Alla Slynko, David Krug, Matthias F. Haefner, Klaus Herfarth, Jürgen Debus, Florian Sterzing, Magnus von Knebel Doeberitz, Elena‐Sophie Prigge, Miriam Reuschenbach,

Head and Neck Cancer Studies

The purpose of this study was to evaluate HPV-DNA and p16(INK4a) (p16) expression as prognostic markers for outcome in patients with anal cancer.From January 2000 to December 2011 a cohort of 105 anal cancer patients was treated with definitive chemoradiation at our institution. Tumor biopsies from 90 patients were analyzed for HPV-DNA by polymerase chain reaction and for p16 expression by immunohistochemistry.Median follow-up was 48.6months (range 2.8-169.1months). HPV-DNA or p16-expression was found in 75 anal cancers each (83.3%), concordance was detectable in 70 tumors (77.8%). Significantly improved overall survival (OS) [77.1% vs. 51.4%, p=0.005], progression-free survival (PFS) [64.0% vs. 35.0%, p<0.001] and improved local control [81.0% vs. 55.9%, p=0.023] was found for concomitant HPV- and p16-positive anal carcinomas (cHPPAC) in univariate analysis. Multivariate analysis showed better OS [p=0.015] and PFS [p=0.002] for cHPPAC.The combination of HPV-DNA and p16 can be used as an independent prognostic parameter in anal cancer patients.